EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSPMJG00000016618
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase D3

Ensembl ID : ENSPMJG00000015111
Gene Symbol: PRKD3
3 Cross references
268 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSPMJG00000014775
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSPMJG00000009693
Gene Symbol: PPP3CA
3 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Kinase 2

Ensembl ID : ENSPMJG00000011788
Gene Symbol: PTK2
3 Cross references
324 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPMJG00000007627
Gene Symbol: PTPN11
3 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPMJG00000012633
Gene Symbol: PTPRB
3 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2x 3

Ensembl ID : ENSPMJG00000006520
Gene Symbol: P2RX3
3 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y1

Ensembl ID : ENSPMJG00000007004
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y12

Ensembl ID : ENSPMJG00000007055
Gene Symbol: P2RY12
3 Cross references
180 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y2

Ensembl ID : ENSPMJG00000001310
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSPMJG00000007912
Gene Symbol: P2RY4
3 Cross references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).